APA (7th ed.) Citation

Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., . . . Tusquets, I. (2018). Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial.

Chicago Style (17th ed.) Citation

Gianni, L., et al. Comparing Neoadjuvant Nab-paclitaxel Vs Paclitaxel Both Followed by Anthracycline Regimens in Women with ERBB2/ HER2-negative Breast Cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) Trial a Randomized Phase 3 Clinical Trial. 2018.

MLA (9th ed.) Citation

Gianni, L., et al. Comparing Neoadjuvant Nab-paclitaxel Vs Paclitaxel Both Followed by Anthracycline Regimens in Women with ERBB2/ HER2-negative Breast Cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) Trial a Randomized Phase 3 Clinical Trial. 2018.